Virginia Medicaid spending on GLP-1 drugs

How much did Virginia Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $230.1 million for GLP-1 drugs paid through Virginia Medicaid in 2025, across at least 227,621 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 123 rows of 329, so these figures are floors.

Pharmacies were reimbursed at least $52.9 million for GLP-1 drugs paid through Virginia Medicaid in 2026 (quarter 1 only, as posted so far), across at least 51,409 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 33 rows of 87, so these figures are floors.

By year and ingredient

2020at least $3,465,988No dataat least $24,010,791at least $6,620,193at least $7,698,135Suppressedat least $162,179at least $78,731at least $42,036,016
2021at least $8,815,424No dataat least $33,041,709at least $19,155,719at least $4,202,461No dataat least $285,221at least $148,689at least $65,649,223
2022at least $18,996,719at least $862,661at least $32,174,054at least $66,137,995at least $1,455,475No data$316,034$106,735at least $120,049,672
2023at least $55,454,331at least $9,599,943at least $28,038,079at least $105,807,565at least $1,036,020No dataat least $239,878at least $64,327at least $200,240,145
2024at least $79,952,371at least $24,767,392at least $13,149,123at least $104,603,643at least $1,141,189No dataat least $167,383Suppressedat least $223,781,102
2025at least $61,108,794at least $40,921,864at least $14,202,970at least $113,536,743at least $236,296No dataat least $102,892Suppressedat least $230,109,559
2026 (Q1)at least $12,271,544at least $12,210,148at least $3,508,318at least $24,908,389SuppressedNo data$14,334Suppressedat least $52,912,733

By product, 2025

Ozempicat least $27,788,205at least 28,9554 of 28
Rybelsusat least $2,307,529at least 2,3969 of 21
Wegovyat least $31,013,060at least 24,20915 of 40
Mounjaroat least $28,658,631at least 27,59530 of 64
Zepboundat least $12,263,233at least 11,79523 of 47
Liraglutide (generic name listing)at least $1,842,758at least 3,9289 of 33
Saxendaat least $10,204,827at least 8,7832 of 8
Victozaat least $2,155,385at least 3,6097 of 15
Trulicityat least $113,536,743at least 115,90310 of 48
Bydureon$52,886680 of 2
Byettaat least $146,984at least 1786 of 8
Exenatide (generic name listing)at least $36,426at least 533 of 6
Soliquaat least $102,892at least 1491 of 5
XultophySuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $56,538,392at least 56,04528 of 79
Q2 2025at least $54,409,934at least 53,52529 of 79
Q3 2025at least $60,609,520at least 59,97734 of 86
Q4 2025at least $58,551,713at least 58,07432 of 85

By quarter, 2026 (posted so far)

Q1 2026at least $52,912,733at least 51,40933 of 87

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.